This article is more than 5 years old. Information may no longer be current.

Ista reports 171% increase in Q2 net revenue

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — Ista Pharmaceuticals Inc. reported net revenues for the second quarter of 2006 increased 171% over the same period 2005 to $7.6 million, according to a press release.

The increase in revenue was driven by key product sales. Sales of Xibrom (bromfenac ophthalmic solution 0.09%) netted $4.3 million in sales. Sales of Istalol (timolol maleate 0.5%) netted $2.1 million in sales, and Vitrase (hyaluronidase) netted $1.1 million.

Despite the improved performance, the company suffered second quarter net losses of $9.2 million, or $0.35 per share, an improvement compared with a net loss of $10.4 million, or $0.40 per share, for the second quarter of 2005, according to the release.